Ulrike I. Attenberger1, Val M. Runge2,
Jonathan Williams3, Henrik J. Michaely
1Department of Clinical Radiology and
Nuclear Medicine, University Medical Center Manheim, Germany, Mannheim,
Baden-Wrttemberg, Germany; 2Scott & White Clinic and
Hospital, Texas A&M University Health Science Center, Department of
Radiology , Temple, TX, United States; 3Department of Radiology, ,
Scott & White Clinic and Hospital, Texas A&M University Health
Science Center, Temple, TX, United States
Regarding
nephrogenic systemic fibrosis (NSF), the injected dose level becomes very
important, since NSF is reported to be related to gadolinium chelate
injection in patients with an impaired renal function, depending upon chelate
stability and dose. With gadobenate dimeglumine, a chelate with transient
protein binding and a higher r1 relaxivity became available. Combining a high
relaxivity chelate and 3 T offers multiple opportunities for dose reduction
without loss in image quality. This was proven in a rat brain glioma model at
1.5 and 3 T, comparing half dose gadobenate dimeglumine vs full dose
gadopentetate dimeglumine, a standard extracellular gadolinium chelate.